Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of “Buy” from Analysts

Personalis, Inc. (NASDAQ:PSNL – Get Rating) has been given a consensus rating of “Buy” by the ten research firms that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $26.71.

A number of research firms have recently commented on PSNL. HC Wainwright reduced their price objective on shares of Personalis from $50.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, February 25th. Zacks Investment Research upgraded shares of Personalis from a “sell” rating to a “hold” rating in a research note on Friday. Bank of America upgraded shares of Personalis from a “neutral” rating to a “buy” rating and reduced their price objective for the stock from $27.00 to $23.00 in a research note on Friday, January 7th. Oppenheimer reduced their price objective on shares of Personalis from $30.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 25th. Finally, BTIG Research restated a “buy” rating and set a $30.00 price objective on shares of Personalis in a research note on Friday, January 7th.

In related news, major shareholder Lightspeed Venture Partners Se purchased 48,989 shares of the stock in a transaction on Wednesday, March 2nd. The shares were purchased at an average cost of $9.96 per share, with a total value of $487,930.44. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Aaron Tachibana sold 4,511 shares of the stock in a transaction dated Wednesday, March 2nd. The shares were sold at an average price of $10.18, for a total transaction of $45,921.98. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,687 shares of company stock worth $57,717. 5.80% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Macquarie Group Ltd. grew its position in shares of Personalis by 128.7% during the 3rd quarter. Macquarie Group Ltd. now owns 1,395 shares of the company’s stock worth $27,000 after purchasing an additional 785 shares in the last quarter. Advisor Group Holdings Inc. grew its position in shares of Personalis by 41.1% during the 3rd quarter. Advisor Group Holdings Inc. now owns 3,920 shares of the company’s stock worth $75,000 after purchasing an additional 1,142 shares in the last quarter. Dark Forest Capital Management LP grew its position in shares of Personalis by 1,014.3% during the 3rd quarter. Dark Forest Capital Management LP now owns 5,393 shares of the company’s stock worth $104,000 after purchasing an additional 4,909 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Personalis during the 4th quarter worth approximately $113,000. Finally, Allegheny Financial Group LTD acquired a new position in shares of Personalis during the 4th quarter worth approximately $146,000. 67.63% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:PSNL traded up $0.23 during trading hours on Tuesday, reaching $6.81. 25,578 shares of the stock were exchanged, compared to its average volume of 450,413. The stock has a market cap of $307.71 million, a PE ratio of -4.66 and a beta of 1.56. Personalis has a twelve month low of $6.46 and a twelve month high of $28.47. The firm has a 50 day moving average of $8.98 and a 200 day moving average of $12.96.

Personalis (NASDAQ:PSNL – Get Rating) last announced its quarterly earnings data on Thursday, February 24th. The company reported ($0.45) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.06. Personalis had a negative net margin of 76.29% and a negative return on equity of 19.72%. During the same period last year, the firm earned ($0.34) EPS. Analysts forecast that Personalis will post -2.49 EPS for the current year.

About Personalis (Get Rating)

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.

See Also